Cleared Traditional

ANTI-ENDOMYSIAL ANTIBODY TEST (K912551) - FDA 510(k) Clearance

Class II Immunology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K912551 · Immco Diagnostics, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1993
Decision
729d
Days
Class 2
Risk

K912551 is an FDA 510(k) clearance for the ANTI-ENDOMYSIAL ANTIBODY TEST. Classified as Multiple Autoantibodies, Indirect Immunofluorescent, Antigen, Control (product code DBL), Class II - Special Controls.

Submitted by Immco Diagnostics, Inc. (Buffalo, US). The FDA issued a Cleared decision on June 9, 1993 after a review of 729 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5660 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Immunology submissions.

View all Immco Diagnostics, Inc. devices

Submission Details

510(k) Number K912551 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 11, 1991
Decision Date June 09, 1993
Days to Decision 729 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
625d slower than avg
Panel avg: 104d · This submission: 729d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DBL Multiple Autoantibodies, Indirect Immunofluorescent, Antigen, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5660
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DBL Multiple Autoantibodies, Indirect Immunofluorescent, Antigen, Control

Devices cleared under the same product code (DBL) and FDA review panel - the closest regulatory comparables to K912551.
Histofluor Rodent LKS Fluorescent Antibody Test System, Image Navigator by Immuno Concepts
K180202 · Immuno Concepts, N.A. , Ltd. · Oct 2018
NOVA LITE ENDOMYSIAL
K980312 · Inova Diagnostics, Inc. · Apr 1998
RIT LIVER, KIDNEY, STOMACH IFA KIT
K955431 · The Binding Site, Ltd. · Apr 1996
ANTI-SKIN ANTIBODY TEST SYSTEM
K811261 · Zeus Scientific, Inc. · Aug 1981